Menu
Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 7,407 | Dovepress* | 6,825+ | 1,264 | 8,089 | |
| PubMed Central* | 582 | 205 | 787 | ||
| Totals | 7,407 | 1,469 | 8,876 | ||
| *Since 20 October 2016 | |||||
View citations on PubMed and Google Scholar